Operating cash flow to fund 2024 debt service and capex
Company: Core Scientific
What the later record shows
Outcome not yet confirmed
The only cash-flow passage covers Q1 2024 and Q1 2025. Nothing shows whether full-year 2024 operating cash flow covered debt service and capex.
Checked November 10, 2026 against filings, releases and reporting published after the claim was made. Quotes are verbatim from the linked documents.
The claim, verbatim
Core Scientific plans for operating cash flow to be sufficient to fund debt service and capital expenditures through 2024.
Source (primary)
core-scientific 8-K exhibit (finalcorzfy2023earningsp.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-11-09)Live source ↗
Quote: “Planned operating cash flow sufficient to fund debt service and capex through 2024”
How we checked this
Checked on November 10, 2026. The cited source supports every part of this claim.
The 2023 snapshot slide states that planned operating cash flow is sufficient to fund debt service and capex through 2024.
Confirmed in the source:
- Core Scientific plans for operating cash flow to be sufficient to fund debt service and capital expenditures through 2024
What we did: Read our cached copy of SEC EDGAR (8-K Ex) (https://www.sec.gov/Archives/edgar/data/1839341/000162828024010544/finalcorzfy2023earningsp.htm) in full (18,367 characters, retrieved November 9, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms core-scientific 8-K exhibit (finalcorzfy2023earningsp.htm)
Quote: “Planned operating cash flow sufficient to fund debt service and capex through 2024”